What Acumetis does

Acumetis is a global life sciences commercialization consulting and analytics firm serving pharmaceutical, biotechnology, and specialty therapeutics organizations. Formed in April 2026 through the combination of five specialist consultancies (Herspiegel, Adivo Associates, Decisive Consulting, Fiecon, and Sixsense Strategy Group) and backed by private equity firm DFW Capital, the company employs over 350 senior experts across the US, Canada, the UK, Europe, and India, supporting more than 150 life sciences clients across 15+ countries and 50+ geographic markets. The company's service portfolio is organized around six integrated practice areas: Commercial Strategy, Launch Excellence, Patient Access & Support Services, Global Value & Access (including HEOR and HTA), Insights & Analytics, and Medical Affairs.

The company's underlying technology stack consists of proprietary cloud-based platforms and self-guided assessment tools layered on top of its consulting engagements. Model Builder (debuted 2018, used in 250+ payer and HTA submissions) automates the design of Excel-based cost-effectiveness and budget impact models; Launch Catalyst provides structured launch planning built on 200+ prior product launches; and NMA Builder enables network meta-analysis without specialized statistical knowledge. Additional assessment tools include the DTP Readiness Assessment, MFN Exposure Assessment, JCA Readiness Assessment, and PICO Prediction Tool, each targeting emerging US and EU regulatory themes. The Acumetis Advisor Network — a curated panel of 1,400+ vetted healthcare stakeholders (payers, PBMs, IDN decision-makers, health economists, former HTA leaders) — supports primary research, mock P&T panels, and advisory engagements.

Acumetis generates revenue through project-based professional services engagements billed at senior expert rates, supplemented by access to its proprietary platforms, with engagements structured as multi-year contracts negotiated per scope. The company sells through direct enterprise engagement by partners and senior leaders, supplemented by thought leadership content, interactive assessment tools (used as lead generation), and major industry conference presence (ISPOR, Fierce Pharma Week). The legal entity is HC Parent Corp., with operations headquartered in Yardley, Pennsylvania.

Name

Acumetis

Legal name

HC Parent Corp.

Website

https://acumetisglobal.com

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

251–500 employees

Short description

Acumetis is a private equity-backed, global life sciences commercialization consulting firm formed in April 2026 by combining five specialist consultancies to serve 150+ pharmaceutical, biotech, and specialty therapeutics clients across 50+ markets with 350+ senior experts and proprietary HEOR and launch platforms.

Ownership category

akta.pro rank

Product category

Life Sciences Commercialization Consulting

NAICS

Marketing Consulting Services (541613)

SIC

Services-Management Consulting Services (8742), Services-Prepackaged Software (7372)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industry

Adherence, Reminders & Engagement Automation (Medication/Follow-up) (HLACAEAJ)

Keywords

• Life sciences consulting
• Market access services
• Health economics consulting
• Pharmaceutical commercialization
• HTA submissions

Headquarters

HQ city

Yardley

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Strategic Consulting Engagements: Acumetis generates revenue through project-based consulting engagements with life sciences organizations. Services span commercial strategy, launch excellence, patient access and support, global value and access, insights and analytics, and medical affairs. Engagements are typically structured as retained consulting projects, advisory board facilitation, strategic workshops, and evidence generation programs. Revenue is derived from professional service fees billed at senior expert rates, with engagements ranging from targeted assessments to comprehensive multi-workstream advisory mandates.
2. Proprietary Software Platforms (Model Builder, NMA Builder, Launch Catalyst): The company offers access to proprietary online platforms including Model Builder (health economic modeling), NMA Builder (network meta-analysis), and Launch Catalyst (launch planning). These tools provide structured, validated outputs and are used both as standalone deliverables within consulting engagements and potentially as licensed access tools. Revenue from platform access complements professional service engagements.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Acumetis provides integrated commercialization consulting and analytics solutions for life sciences and biopharma organizations across the product lifecycle, from early development through launch and beyond. The company delivers strategic advisory services in commercial strategy, launch excellence, patient access and support, global value and access, insights and analytics, and medical affairs, complemented by proprietary technology platforms (Model Builder, NMA Builder, Launch Catalyst) and the Acumetis Advisor Network of 1,400+ vetted healthcare stakeholders.

Product overview

Acumetis is a global life sciences commercialization company that offers an integrated portfolio of consulting services and proprietary technology platforms. The core technology offerings include Model Builder (cloud-based Excel model automation platform for HTA/payer submissions), Launch Catalyst (launch planning platform), and NMA Builder (network meta-analysis tool). These platforms are complemented by six service expertise areas: Commercial Strategy, Launch Excellence, Patient Access & Support Services, Global Value & Access, Insights & Analytics, and Medical Affairs. The company also provides assessment tools including MFN Exposure Assessment, DTP Readiness Assessment, and JCA Readiness Assessment, all powered by proprietary information platforms and the Acumetis Advisor Network of 1,400+ vetted healthcare stakeholders. The company was formed in April 2026 through the merger of five specialist consultancies (Herspiegel, Adivo Associates, Decisive Consulting, Fiecon, and Sixsense Strategy Group).

Differentiator

Problem solved

Functional benefit

Products and services

• Model Builder An online, cloud-based platform that automates the design and building of Excel-based cost-effectiveness and budget impact models for HTA and payer submissions. Reduces human error and consistently produces HTA-ready Excel models.
• Launch Catalyst A launch planning platform built on 200+ launches and thousands of hours of real-world experience. Generates tailored, actionable plans aligned to specific product and strategy, identifies risks early, and supports precision launch execution.
• NMA Builder A network meta-analysis tool that lets life sciences teams run complex network meta-analyses quickly and accurately without specialized statistical knowledge. Features an intuitive interface, validated calculations, and robust reporting for health economics and market access decisions.
• Commercial Strategy Consulting expertise area providing proven commercial leaders who use actionable insight to uncover new angles and design solutions that strengthen operating models, brand performance, and long-term value.
• Launch Excellence Consulting expertise area providing connected insights and practical innovation to identify risks and opportunities, de-risking launch planning and execution to maximize uptake and access.
• Patient Access & Support Services Consulting expertise area leveraging deep understanding of patient access landscapes to design and activate patient access and support programs that remove barriers, unite stakeholders, and accelerate therapy adoption.
• Global Value & Access Consulting expertise area integrating evidence strategy, health economics, and market access to define value, earn coverage, and drive adoption across key markets.
• Insights & Analytics Consulting expertise area combining proprietary information platforms with therapeutic market experts to deliver insights that translate into actionable advantage in rare disease landscapes.
• Medical Affairs Consulting expertise area where scientific acumen and therapeutic market insights shape compelling narratives that educate the market and drive informed behavior change.
• MFN Exposure Assessment A self-guided strategic screening tool designed to help manufacturers evaluate potential Most Favored Nation-related pricing exposure across therapeutic category, reimbursement pathway, Medicare spend, Medicaid status, and MFN participation considerations.
• DTP Readiness Assessment A self-guided, fact-based framework that evaluates whether, where, and how a product can succeed in a direct-to-patient model, assessing four core pillars: access dynamics, behavioral readiness, digital e-pharmacy enablement, and telehealth potential.
• JCA Readiness Assessment An assessment tool to identify capability gaps across evidence planning, organisational structure, stakeholder engagement, and submission processes for EU Joint Clinical Assessment readiness.

Quantifiable outcome

• Over 200 product launches supported by the five founding firms over two decades
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature10 records

Partnerships

One partnership is on record.

• BrandingBusinesscoreStrategic or Co-development Partner · 14 April 2026BrandingBusiness, a B2B brand strategy firm, led the brand development for Acumetis, including name derivation from Greek words, corporate messaging framework, logo, and visual identity system with the tagline 'Reframe what's possible.' The partnership created the unified Acumetis brand from the integration of five specialist consultancies.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• IQVIA: Global life sciences services giant combining real-world data, clinical research, and commercialization consulting. Directly comparable as the dominant full-service life sciences commercialization partner serving the same pharma and biotech clients across market access, HEOR, and commercial strategy — but at materially larger scale.
• McKinsey & Company (Pharma Practice): Global management consulting firm with one of the largest pharma and medical products practices. Competes for top-tier commercial strategy, launch, and market access engagements across enterprise pharma — broader portfolio but overlapping capability in commercialization advisory.
• Boston Consulting Group (BCG) — Healthcare Practice: Top-tier global consultancy with a deep healthcare and life sciences practice offering commercial strategy, market access, and operations consulting. Competes at the enterprise pharma level for the same strategic commercialization mandates.

Direct peers

• Simon-Kucher & Partners: Global consulting firm with strong life sciences practice focused on pricing, market access, and commercial strategy. Direct peer for pricing strategy, market access, and launch excellence engagements with pharma and biotech clients.
• Analysis Group: Economic, financial, and strategy consulting firm with a sizable Health Care and Life Sciences practice. Comparable in HEOR, HTA submissions, health economics modeling, and outcomes research for the same pharmaceutical and biotech client base.
• Evidera (PPD / Thermo Fisher Scientific): HEOR, market access, and evidence synthesis consultancy serving pharma and biotech. Closely comparable in HEOR consulting, HTA/payer submission support, and patient-centered research — a direct rival for Acumetis' Global Value & Access practice.
• Trinity Life Sciences: Life sciences strategy and insights consultancy providing commercial strategy, launch planning, and market access support. Highly comparable in service mix (commercial strategy, market access, evidence synthesis) and client base (large pharma and emerging biotech).
• ZS Associates: Management consulting firm focused on sales, marketing, and commercial strategy for life sciences clients. Direct competitor in pharma commercial strategy, launch excellence, and market access advisory — targeting the same enterprise pharma buyers with comparable expertise areas.
• ClearView Healthcare Partners: Life sciences strategy consulting firm serving pharma, biotech, and medtech with commercial strategy, market access, and new product planning. Closely comparable boutique competitor serving similar mid-sized and enterprise pharma clients.
• Charles River Associates (CRA): Economic and management consulting firm with a substantial Life Sciences practice offering HEOR, market access, pricing, and commercial strategy. Directly competes for HEOR and HTA submission engagements with comparable specialty therapeutic-area depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acumetis